Novamigra
Therapeutics
a pioneering biopharmaceutical company developing a best-in-class novel therapy for migraine prevention
Data confirmed derisked clinical development
Data confirmed derisked clinical development
Data confirmed derisked clinical development
Enter first-in-human trial in Q1 2026
Enter first-in-human trial in Q1 2026
Enter first-in-human trial in Q1 2026
Novel mechanism of action
Novel mechanism of action
Novel mechanism of action
Targeting around 50% of resistant patients
Targeting around 50% of resistant patients
Targeting around 50% of resistant patients
High unmet medical need in migraine therapy
Migraine impacts ca. 1 billion patients worldwide, out of which around 40% should be treated prophylactically.
The global market size for migraine prophylaxis is expected to reach 10 billion USD by 2027 according to Nature Reviews.
Migraine impacts ca. 1 billion patients worldwide, out of which around 40% should be treated prophylactically.
The global market size for migraine prophylaxis is expected to reach 10 billion USD by 2027 according to Nature Reviews.


Zalán Péterfi MD PhD


Zalán Péterfi MD PhD


Sándor Farkas MD PhD


Sándor Farkas MD PhD


Natalia Novac PhD


Natalia Novac PhD


Marc Debelle MD PhD


Marc Debelle MD PhD


Tamás Csikai


Tamás Csikai
Strong leadership with impressive track record
Strong leadership with impressive track record
Strong leadership with impressive track record
Novamigra team prides itself with 100+ years Pharma R&D experience with impressive multiple assets brought to clinical phase & 2 taken to market
Novamigra team prides itself with 100+ years Pharma R&D experience with impressive multiple assets brought to clinical phase & taken to market
The Novamigra team brings over 100 years of combined pharmaceutical R&D experience, having successfully advanced 10 assets to the clinical phase and brought to market.



Zalán Péterfi MD PhD



Sándor Farkas MD PhD



Natalia Novac PhD



Marc Debelle MD PhD



Tamás Csikai



Zalán Péterfi MD PhD



Sándor Farkas MD PhD



Natalia Novac PhD



Marc Debelle MD PhD



Tamás Csikai



Zalán Péterfi MD PhD







Zalán Péterfi MD PhD




Latest update
Novamigra Tx Announces Successful Pre-IND Meeting with FDA, Paving the Way for Accelerated Clinical Development

Novamigra Tx Announces Successful Pre-IND Meeting with FDA, Paving the Way for Accelerated Clinical Development

Novamigra Tx Announces Successful Pre-IND Meeting with FDA, Paving the Way for Accelerated Clinical Development

Novamigra Tx Announces Successful Pre-IND Meeting with FDA, Paving the Way for Accelerated Clinical Development

Novamigra Tx Announces Successful Pre-IND Meeting with FDA, Paving the Way for Accelerated Clinical Development
